Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 24, Issue 31, 2006, Pages 5025-5033

  Fanucchi, Michael P ^b   Fossella, Frank V ^b   Belt, Robert ^b   Natale, Ronald ^b   Fidias, Panos ^b   Carbone, David P ^b   Govindan, Ramaswamy ^b   Raez, Luis E ^b   Robert, Francisco ^b   Ribeiro, Maria ^b   Akerley, Wallace ^b   Kelly, Karen ^b   Limentani, Steven A ^b   Crawford, Jeffrey ^b   Reimers, Hans Joachim ^b   Axelrod, Rita ^b   Kashala, Oscar ^b   Sheng, Shihong ^b   Schiller, Joan H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DOCETAXEL; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; VOMITING; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; TAXOIDS; TREATMENT OUTCOME; UNITED STATES;

EID: 33750945704     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.1853     Document Type: Article

References (49)

1. American Cancer Society: Cancer Facts and Figures 2005. American Cancer Society, Atlanta, GA, 2005
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481-488, 2005
3. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
4. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:3016-3024, 2003
5. Lilenbaum RC, Herndon JE II, List MA, et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The cancer and leukemia group B (study 9730). J Clin Oncol 23:190-196, 2005
6. Schenkein DP: Use of proteasome inhibition in the treatment of lung cancer. Clin Lung Cancer 6:S89-S96, 2004 (suppl 2)
7. Bunn PA Jr: Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 20:23S-33S, 2002
8. Bunn PA Jr: Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol 20:3565-3567, 2002
9. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
10. Waechter F, Passweg J, Tamm M, et al: Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 127:738-747, 2005
11. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 23:2s, 2005 (suppl; abstr LBA4)
12. Belani CP, Eckardt J: Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer 46:S3-S11, 2004 (suppl 2)
13. Wakelee H, Ramalingam S, Belani CP: Docetaxel in advanced non-small cell lung cancer. Expert Rev Anticancer Ther 5:13-24, 2005
14. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
15. Dancey J, Shepherd FA, Gralla RJ, et al: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 43:183-194, 2004
16. Cohen MH, Johnson JR, Wang YC, et al: FDA drug approval summary: Pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10:363-368, 2005
17. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
18. Shepherd FA, Rodrigues Pereira J, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
19. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
20. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
21. Jagannath S, Barlogie B, Berenson J, et al: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127: 165-172, 2004
22. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
23. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
24. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
25. Cusack JC: Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29:21-31, 2003 (suppl 1)
26. Lara PN Jr, Davies AM, Mack PC, et al: Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol 31:40-46, 2004
27. Papandreou CN, Daliani DD, Nix D, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004
28. Park DJ, Lenz HJ: The role of proteasome inhibitors in solid tumors. Ann Med 36:296-303, 2004
29. Adams J: The proteasome: A suitable antineoplastic target. Nat Rev Cancer 4:349-360, 2004
30. Mack PC, Davies AM, Lara PN, et al: Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 41:S89-S96, 2003 (suppl 1)
31. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622, 1999
32. Ling YH, Liebes L, Jiang JD, et al: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154, 2003
33. Ling YH, Liebes L, Ng B, et al: PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849, 2002
34. Mortenson MM, Schlieman MG, Virudachalam S, et al: Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54:343-353, 2004
35. Yang Y, Ikezoe T, Saito T, et al: Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/ c-Jun/AP-1 signaling. Cancer Sci 95:176-180, 2004
36. Denlinger CE, Rundall BK, Keller MD, et al: Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78:1207-1214, 2004
37. Denlinger CE, Rundall BK, Jones DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 128:740-748, 2004
38. Denlinger CE, Keller MD, Mayo MW, et al: Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 127:1078-1086, 2004
39. Gumerlock P, Kawaguchi T, Moisan L, et al: Mechanisms of enhanced cytotoxicity from docetaxel/ PS-341 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 21:1214, 2002 (abstr 304)
40. Gumerlock PH, Kimura T, Holland WS, et al: Differential in vivo activity of docetaxel plus PS-341 combination therapy in non-small cell lung carcinoma (NSCLC) xenografts. J Clin Oncol 22:652s, 2004 (suppl; abstr 7144)
41. Nawrocki ST, Sweeney-Gotsch B, Takamori R, et al: The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 3:59-70, 2004
42. Pink M, Pien C, Ona V, et al: PS-341 enhances chemotherapeutic effect in human xenograft models. Proc AACR 43:158, 2002 (abstr 787)
43. Stevenson JP, Nho CW, Johnson SW, et al: Phase II/ pharmacodynamic trial of PS-341 (bortezomib, Velcade) in advanced non-small cell lung cancer. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004
44. Albanell J, Baselga J, Guix M, et al: Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc Am Soc Clin Oncol 22:16, 2003 (abstr 63)
45. Dreicer R, Roth B, Petrylak D, et al: Phase I/II trial of velcade plus docetaxel in patients with advanced androgen-independent prostate cancer. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004
46. Fanucchi M, Belt R, Fossella F, et al: Phase 2 study of bortezomib ± docetaxel in previously treated advanced non-small cell lung cancer: Interim analysis. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004
47. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
48. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003 [Erratum: J Clin Oncol 22:4811, 2004]
49. Smit EF, Mattson K, von Pawel J, et al: ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: A phase II study. Ann Oncol 14:455-460, 2003